FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282923861> ?p ?o ?g. }

• W4282923861 endingPage "561" @default.
• W4282923861 startingPage "549" @default.
• W4282923861 abstract "Cancer is a significant public health problem and ranks as a leading cause of death globally. Multidrug resistance (MDR) affects the therapeutic potential of conventional chemotherapeutic agents in cancer chemotherapy. Receptor tyrosine kinases (RTKs) are enzymes whose aberrant activation contributes to the tumorigenesis of various types of cancers. The ability of several RTKs, such as c-Met, to reverse ABC transporters mediated MDR was shown before. We aimed to explore the ability of c-Met inhibitors to circumvent MDR in cancer by inhibiting the ABCB1 transporter using in silico studies.Docking virtual screening of several potent and structurally diverse c-Met inhibitors were applied to find repurposed candidates to target the ATP binding sites and drug-substrate binding pockets of the ABCB1 transporter. The selected candidate was subjected to molecular dynamics simulations.Based on docking findings, among 19 clinical c-Met inhibitors, several drugs, particularly golvatinib, exerted the affinity to both ATP binding sites in the nucleotide-binding domains (NBDs) as well as the drug-substrate binding site in the transmembrane domains (TMDs). Moreover, several non-clinical c-Met inhibitors obtained from the ChEMBL database had strong interactions with TMDs and NBDs, among which CHEMBL1950194 and CHEMBL2385194 compounds showed the highest binding affinity, respectively. Additionally, as a potential repositioning drug, MD simulation studies of golvatinib, corroborated the docking results.We applied docking and molecular dynamics simulations to screen the potential c-Met inhibitors as the MDR reversing agents targeting ATP and drug-substrate binding sites, and the results suggested several repurposed candidate drugs." @default.
• W4282923861 created "2022-06-16" @default.
• W4282923861 creator A5005759043 @default.
• W4282923861 creator A5023364723 @default.
• W4282923861 creator A5032620524 @default.
• W4282923861 creator A5039407091 @default.
• W4282923861 date "2022-06-15" @default.
• W4282923861 modified "2023-09-30" @default.
• W4282923861 title "<i>In silico</i> screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents" @default.
• W4282923861 cites W2006434892 @default.
• W4282923861 cites W2028629022 @default.
• W4282923861 cites W2044172327 @default.
• W4282923861 cites W2045683699 @default.
• W4282923861 cites W2060391884 @default.
• W4282923861 cites W2111940011 @default.
• W4282923861 cites W2132629607 @default.
• W4282923861 cites W2169678694 @default.
• W4282923861 cites W2174049160 @default.
• W4282923861 cites W2331067690 @default.
• W4282923861 cites W2599363274 @default.
• W4282923861 cites W2779730509 @default.
• W4282923861 cites W2782736845 @default.
• W4282923861 cites W2791331573 @default.
• W4282923861 cites W2791739854 @default.
• W4282923861 cites W2795353688 @default.
• W4282923861 cites W2796552195 @default.
• W4282923861 cites W2886690891 @default.
• W4282923861 cites W2908537516 @default.
• W4282923861 cites W2913173637 @default.
• W4282923861 cites W2941939748 @default.
• W4282923861 cites W2998373981 @default.
• W4282923861 cites W3001778677 @default.
• W4282923861 cites W3022831706 @default.
• W4282923861 cites W3032966509 @default.
• W4282923861 cites W3110956079 @default.
• W4282923861 cites W3128646645 @default.
• W4282923861 cites W3137711059 @default.
• W4282923861 cites W3021579783 @default.
• W4282923861 doi "https://doi.org/10.1080/10799893.2022.2086988" @default.
• W4282923861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35704515" @default.
• W4282923861 hasPublicationYear "2022" @default.
• W4282923861 type Work @default.
• W4282923861 citedByCount "2" @default.
• W4282923861 countsByYear W42829238612023 @default.
• W4282923861 crossrefType "journal-article" @default.
• W4282923861 hasAuthorship W4282923861A5005759043 @default.
• W4282923861 hasAuthorship W4282923861A5023364723 @default.
• W4282923861 hasAuthorship W4282923861A5032620524 @default.
• W4282923861 hasAuthorship W4282923861A5039407091 @default.
• W4282923861 hasConcept C101544691 @default.
• W4282923861 hasConcept C103697762 @default.
• W4282923861 hasConcept C104317684 @default.
• W4282923861 hasConcept C107824862 @default.
• W4282923861 hasConcept C133936738 @default.
• W4282923861 hasConcept C149011108 @default.
• W4282923861 hasConcept C159110408 @default.
• W4282923861 hasConcept C170493617 @default.
• W4282923861 hasConcept C184235292 @default.
• W4282923861 hasConcept C185592680 @default.
• W4282923861 hasConcept C2775905019 @default.
• W4282923861 hasConcept C41685203 @default.
• W4282923861 hasConcept C42362537 @default.
• W4282923861 hasConcept C44312359 @default.
• W4282923861 hasConcept C501593827 @default.
• W4282923861 hasConcept C55493867 @default.
• W4282923861 hasConcept C70721500 @default.
• W4282923861 hasConcept C71924100 @default.
• W4282923861 hasConcept C74187038 @default.
• W4282923861 hasConcept C86803240 @default.
• W4282923861 hasConcept C98274493 @default.
• W4282923861 hasConceptScore W4282923861C101544691 @default.
• W4282923861 hasConceptScore W4282923861C103697762 @default.
• W4282923861 hasConceptScore W4282923861C104317684 @default.
• W4282923861 hasConceptScore W4282923861C107824862 @default.
• W4282923861 hasConceptScore W4282923861C133936738 @default.
• W4282923861 hasConceptScore W4282923861C149011108 @default.
• W4282923861 hasConceptScore W4282923861C159110408 @default.
• W4282923861 hasConceptScore W4282923861C170493617 @default.
• W4282923861 hasConceptScore W4282923861C184235292 @default.
• W4282923861 hasConceptScore W4282923861C185592680 @default.
• W4282923861 hasConceptScore W4282923861C2775905019 @default.
• W4282923861 hasConceptScore W4282923861C41685203 @default.
• W4282923861 hasConceptScore W4282923861C42362537 @default.
• W4282923861 hasConceptScore W4282923861C44312359 @default.
• W4282923861 hasConceptScore W4282923861C501593827 @default.
• W4282923861 hasConceptScore W4282923861C55493867 @default.
• W4282923861 hasConceptScore W4282923861C70721500 @default.
• W4282923861 hasConceptScore W4282923861C71924100 @default.
• W4282923861 hasConceptScore W4282923861C74187038 @default.
• W4282923861 hasConceptScore W4282923861C86803240 @default.
• W4282923861 hasConceptScore W4282923861C98274493 @default.
• W4282923861 hasIssue "6" @default.
• W4282923861 hasLocation W42829238611 @default.
• W4282923861 hasLocation W42829238612 @default.
• W4282923861 hasOpenAccess W4282923861 @default.
• W4282923861 hasPrimaryLocation W42829238611 @default.
• W4282923861 hasRelatedWork W1714666523 @default.
• W4282923861 hasRelatedWork W1971792277 @default.

• next